HOOKIPA Pharma Inc. announced positive updated results from its Phase 1/2 clinical trial of HB-200 for the treatment of human papillomavirus 16 positive (HPV16+) head and neck cancers. HB-200 in combination with pembrolizumab received Fast Track Designation from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency for the treatment of first-line HPV16+ recurrent/metastatic oropharyngeal squamous cell carcinoma. These designations are supported by preliminary clinical evidence from the Phase 1/2, open-label, clinical trial (NCT04180215) evaluating safety, T cell response, and efficacy based on objective response rate (ORR) and disease control rate (DCR) as defined by RECIST 1.1. and iRECIST.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.64 USD | +0.30% |
|
-9.37% | -20.99% |
06-05 | HC Wainwright Adjusts Price Target on HOOKIPA Pharma to $6 From $5, Maintains Buy Rating | MT |
06-04 | Transcript : HOOKIPA Pharma Inc. - Special Call |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.99% | 63.33M | |
+55.19% | 815B | |
+46.51% | 654B | |
-6.09% | 354B | |
+21.92% | 337B | |
+19.10% | 247B | |
+3.84% | 229B | |
+13.99% | 219B | |
+10.86% | 171B | |
-2.78% | 159B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- HOOKIPA Pharma Inc. Announces Positive Clinical Data to Be Presented At the American Society for Clinical Oncology 2024 Annual Meeting